While PARP inhibitor-based therapy holds great promise for the treatment of HR-deficient cancers, a major obstacle is that clinical testing of these tumors often reveals numerous VUS in BRCA1, BRCA2, and PALB2, for which the effect on HR and the response to PARP inhibitor-based therapy is often unclear. The gene discussed is BRCA2; the disease is cancer.